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Volume 55, Number 1 Abstracts 293and 6 to 8 hours after CEA or CAS. Biomarkers were also assessed any time
there was clinical evidence of cardiac ischemia. MI was defined as biomarker
elevation plus ECG evidence of ischemia or chest pain. Cardiac biomarker-
only elevation was defined as elevation of cardiac biomarkers without chest
pain or ECG abnormalities. Among the 2502 patients randomized in
CREST, 14 MIs were associated with CAS and 28 MIs were associated with
CEA (HR, 0.5; 95% CI, 0.26-0.94; P .032). The median biomarker ratio
in patients withMIs was 40 times the upper limit of normal. Eight additional
CAS patients and 12 additional CEA patients had biomarker-only events
(HR, 0.66; 95% CI, 0.27-1.61; P  0.36). Median biomarker ratio com-
pared with normal was 14 times the upper limit of normal for the patients
with biomarker-only elevation. When comparing patients with MI vs those
without biomarker elevation, mortality was higher over 4 years (HR, 3.4;
95% CI, 1.67-6.92). Mortality was also higher for those patients with
biomarkers-only end points compared with those with no biomarker eleva-
tions (HR, 3.57; 95% CI, 1.46-8.68). Adjustments for baseline risk factors
indicated that MI and biomarker-only elevations were still independent risk
factors for increased mortality.
Comment: Even a small MI after a noncardiac intervention is associ-
ated with increased late mortality. The data do not imply a cause-and-effect
relationship. It is reasonable to postulate a periprocedural MI or biomarker-
only elevations are likely markers of more extensive atherosclerotic disease.
One cannot determine whether an ischemic event itself, in relationship to
performance of a procedure, increases the late risk of this elevated athero-
sclerotic burden. The data do suggest that one should think twice about
performing any form of carotid artery revascularization in patients felt to be
at increased cardiac risk because of likely decreased long-term survival in
such patients.
Placement and Removal of Inferior Vena Cava Filters: National Trends
in the Medicare Population
Duszak R Jr, Parker L, Levin DC, et al. J Am Coll Radiol 2011;8:483-9.
Conclusion:The frequency of inferior vena cava (IVC) filter placement
has doubled during the past decade in theMedicare population. Volume has
more than tripled in hospital outpatients, and IVC filters are not commonly
removed in the Medicare population.
Summary: The availability of retrievable IVC filters has lowered the
threshold for filter placement among many physicians. Recent studies of the
frequency of IVC filter placement have focused on trauma patients (Antevil
JL, J Trauma 2006;60:35-40; Karmy-Jones R et al, J Trauma 2007;62:17-
25). TheMedicare population, however, is a much larger group than trauma
patients; thus, patterns of filter placement in Medicare patients are pertinent
to discussions of utilization of health care resources. The authors therefore
sought to evaluate placement and removal of IVC filters in the Medicare
population. They usedMedicare summary claims data from 1999 to 2008 to
identify the frequency of IVC filter placement. They performed analysis
according to the specialist placing the filter (radiology, surgery, cardiology,
and all others) as well as site of service. They used claims from 2003 (the first
year the Food and Drug Administration cleared retrievable labeling for IVC
filters) through 2008. Modeling was used to estimate a frequency range of
removal procedures. They also evaluated trends of placement and removal
over time.
Between 1999 and 2008, total Medicare fee for service beneficiary
frequency of IVC filter placement procedures increased from 30,756 to
65,041 (111.5%). Volumes increased by all specialties: radiologists, 16,531
to 36,832 (123%); surgeons, 11,295 to 22,606 (100%); and cardiolo-
gists, 1025 to 4236 (313%). Hospital inpatient volumes increased from
26,511 to 56,774 (114%). In-hospital outpatient volumes increased from
2,286 to 7,524 (229%). In 2008, with 65,041 filters placed, only an
estimated 801 to 3,339 (1.2%-5.1%) were removed.
Comment: The number of IVC filters placed in Medicare patients has
increased dramatically. Very few are removed. It is unclear if this indicates
the indications for IVC filters in Medicare patients mirror more traditional
indications for placement of permanent IVC filters. It is rumored reimburse-
ment for placement of IVC filters will soon be dramatically reduced. How-
ever, because a large percentage of filters are still placed by radiologists, who
generally do not make the decision to place the filter, decreased reimburse-
ment for filters may lower the overall cost toMedicare but may not influence
many referring physicians’ choice to have the filter placed. It is likely that
with the aging population and greater numbers of Medicare beneficiaries,
the trend of more filters being placed in Medicare patients will continue.
Pravastatin Reduces Marfan Aortic Dilation
Mcloughlin D, McGuinness J, Byrne J, et al. Circulation 2011;124(suppl
1):S168-73.
Conclusion: Statins attenuate aortic root dilation in a mouse model of
Marfan syndrome.
Summary: Marfan syndrome derives from a relative lack of or abnor-
mal fibrillin-1, resulting in vascular smoothmuscle cells losing their ability to
sense aortic wall strain. This leads to excessive transforming growth factor-
w
tTGF-) release from the connective tissue matrix, resulting in excessive
ctivation of smooth muscle cells and an inappropriate and haphazard
emodeling process. The result is progressive dilation and weakening of the
orta and aortic root. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A
eductase inhibitor (statin), has pleiotropic anti-inflammatory effects. It
educes cardiac expression of TGF- (Yu Y, et al, J Am Coll Cardiol
004;44:904-13). Because TGF- dysregulation can be attributed to fibril-
in-1 deficiency, pravastatin is a potential therapeutic agent to prevent aortic
omplications of Marfan syndrome. The authors examined the efficacy and
echanisms of action of statins in attenuating aortic root dilation in Marfan
yndrome and compared these effects with those of losartan, a medication
nown to have favorable effects in the mouse model of Marfan syndrome.
The authors usedMarfan mice heterozygous for a mutant allele encod-
ng a cysteine substitution in fibrillin-1. The mice were treated daily from 6
eeks old with pravastatin (0.5 g/L) or losartan (0.6 g/L). End points were
ortic root diameter (n  25), aortic thickness and architecture (n  10),
lastin volume (n  5), dp/dt max (maximal rate of change of pressure by
ardiac catheter; n 20), and ultrastructure analysis with histology (electron
icroscopy; n  5). Aortic root diameters of untreated Marfan mice were
ignificantly increased compared with normal mice (0.161  0.001 vs
.252  0.004 cm; P  .01). Pravastatin (0.22  0.003 cm; P  .01) and
osartan (0.221  0.004 cm; P  0.01) produced reductions in aortic root
ilation. Elastin volume was preserved within the medial layer by pravastatin
0.23 0.02) and losartan (0.29 0.03) vs untreatedMarfan mice (0.19
.02; P .01) and normalmice (0.27 0.02). Pravastatin and losartan both
educed rough endoplasmic reticulum in smooth muscle cells compared
ith untreated Marfan mice (P  .01).
Comment: Pravastatin attenuates aortic root dilation and preserves
ortic elastin in a mouse model of Marfan syndrome. Losartan also reduces
ortic root dilation to the same degree but seemed to have a greater effect of
reserving elastin within the aortic wall and in reducing aortic wall thicken-
ng. Both medications likely work through modulation of TGF-. Losartan,
ith its antihypertensive effect and reduction in pulse pressure and hemo-
ynamic strain on the aortic root, should have more favorable long-term
ffects. Statins, however, are well tolerated in the long-term and now need to
e investigated as both monotherapy and as combination therapy with
osartan in animal models of Marfan syndrome and eventually in humans
ith Marfan syndrome.
ole of conservative management in traumatic aortic injury: Compar-
son of long-term results of conservative, surgical, and endovascular
reatment
osquera VX, Marini M, Lopez-Perez JM, et al. J Thorac Cardiovasc Surg
011;142:614-21.
Conclusion: Nonoperative management of thoracic aortic injury can
ave acceptable survival in carefully selected patients but at the expense of a
arked trend for late aortic-related complications.
Summary: Limited studies of blunt thoracic aortic trauma suggest, at
east in the short-term, a conservative approach with medical management
nly of blunt thoracic aortic trauma may be appropriate. Such studies have
ocused on in-hospital mortality and morbidity with little long-term follow-
p. The current study is of 30 years of management of blunt thoracic injury
n a single center. Survival and cardiovascular complications of patients with
cute thoracic aortic injury who were conservatively managed and those who
nderwent surgical or endovascular repair are reported. There were 66
atients with acute traumatic thoracic injury spanning January 1980 to
ecember 2009; of these, 37 were treated conservatively, 22 surgically, and
with an endovascular repair. All groups were similar in age, sex, revised
rauma score, injury severity score, and trauma injury severity score. Mortal-
ty in the hospital was 21.6% in the conservative group, 22.7% in the surgical
roup, and 14.3% in the endovascular group (P  .57). In-hospital aortic-
elated complications occurred only in the conservative management group.
edian follow-up was 75 months (range, 5-327 months). Survival at 1, 5,
nd 10 years was 75.6%, 72.3%, and 66.7% in the conservative group and
7.2%, 77.2% and 77.2% in the surgical group. In the endovascular group,
urvival was 85.7% at 1 and 5 years (P  .18). No new interventions on the
orta were required in the surgical or endovascular groups. However, 37.9%
f the conservative group had an aortic-related complication that required
urgery or caused patient death during follow-up. Survival free from aortic-
elated complications in the conservative group was 93% at 1 year, 88.5% at
years, and 51.2% at 10 years. A trauma score-injury severity score50% on
dmission (HR, 1.49; P  .042) and initial type of aortic lesion (HR, 2.94;
 .002) were risk factors for late aorta-related complications. Late aortic
omplications occurred in two peaks: during the first week and between 1
nd 3 months after injury. Late aortic-related complications were two free
ortic ruptures, one progression of an initially localized dissection with distal
erfusion impairment, and eight cases of post-traumatic pseudoaneurysm.
he dissection progression and both free aortic ruptures led to patient death.
ll pseudoaneurysms were repaired surgically.
Comment: There appear to be more late aortic-related complications
ith conservative management of blunt thoracic aortic trauma. The poten-
ial benefit of conservative management in selected patients is therefore
